Angiotensin

Angiotensin is a peptide hormone that causes vasoconstriction and an increase in blood pressure. It is part of the renin–angiotensin system, which regulates blood pressure. Angiotensin also stimulates the release of aldosterone from the adrenal cortex to promote sodium retention by the kidneys.

AGT
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 2WXW, 2X0B, 4APH,%%s1N9U, 1N9V,%%s1N9V, 1N9U, 3CK0, 4AA1, 4APH, 5E2Q
Identifiers
Aliases	AGT, ANHU, SERPINA8, hFLT1, angiotensinogen
External IDs	MGI: 87963 HomoloGene: 14 GeneCards: AGT
Gene location (Human) Chr. Chromosome 1 (human)[1] Band 1q42.2 Start 230,702,523 bp[1] End 230,714,122 bp[1]
Gene location (Mouse) Chr. Chromosome 8 (mouse)[2] Band 8 E2|8 72.81 cM Start 124,556,534 bp[2] End 124,569,706 bp[2]
RNA expression pattern More reference expression data
Gene ontology Molecular function • GO:0001948 protein binding • serine-type endopeptidase inhibitor activity • type 1 angiotensin receptor binding • hormone activity • superoxide-generating NADPH oxidase activator activity • growth factor activity • type 2 angiotensin receptor binding • sodium channel regulator activity • angiotensin receptor binding • receptor ligand activity Cellular component • cytoplasm • extracellular exosome • blood microparticle • extracellular • cytosol • extracellular region • collagen-containing extracellular matrix Biological process • uterine smooth muscle contraction • renal system process • vasoconstriction • GO:0048554 positive regulation of catalytic activity • positive regulation of cardiac muscle hypertrophy • cell surface receptor signaling pathway • cellular response to mechanical stimulus • stress-activated MAPK cascade • artery smooth muscle contraction • regulation of systemic arterial blood pressure by renin-angiotensin • regulation of apoptotic process • negative regulation of neurotrophin TRK receptor signaling pathway • regulation of long-term neuronal synaptic plasticity • positive regulation of renal sodium excretion • positive regulation of fibroblast proliferation • cellular sodium ion homeostasis • ERK1 and ERK2 cascade • activation of phospholipase C activity • angiotensin maturation • positive regulation of extracellular matrix constituent secretion • positive regulation of blood pressure • negative regulation of cell growth • regulation of norepinephrine secretion • female pregnancy • negative regulation of tissue remodeling • regulation of heart rate • smooth muscle cell proliferation • regulation of calcium ion transport • regulation of transmission of nerve impulse • cell growth involved in cardiac muscle cell development • response to muscle activity involved in regulation of muscle adaptation • positive regulation of nitric oxide biosynthetic process • cytokine secretion • angiotensin-mediated drinking behavior • cell-cell signaling • aging • vasodilation • positive regulation of cell proliferation • fibroblast proliferation • negative regulation of angiogenesis • positive regulation of superoxide anion generation • positive regulation of L-lysine import across plasma membrane • positive regulation of cardiac muscle cell apoptotic process • positive regulation of vascular smooth muscle cell proliferation • positive regulation of cytosolic calcium ion concentration • negative regulation of endopeptidase activity • positive regulation of vascular associated smooth muscle cell migration • regulation of molecular function • regulation of lipid metabolic process • positive regulation of blood vessel diameter • positive regulation of L-arginine import across plasma membrane • regulation of receptor activity • positive regulation of neuron projection development • response to estradiol • cellular response to angiotensin • protein import into nucleus • associative learning • operant conditioning • positive regulation of insulin receptor signaling pathway • regulation of extracellular matrix assembly • positive regulation of cholesterol esterification • phospholipase C-activating G-protein coupled receptor signaling pathway • blood vessel remodeling • positive regulation of reactive oxygen species metabolic process • positive regulation of extrinsic apoptotic signaling pathway • positive regulation of cellular protein metabolic process • positive regulation of branching involved in ureteric bud morphogenesis • kidney development • positive regulation of transcription, DNA-templated • positive regulation of peptidyl-tyrosine phosphorylation • positive regulation of inflammatory response • positive regulation of protein tyrosine kinase activity • regulation of blood pressure • positive regulation of macrophage derived foam cell differentiation • regulation of vasoconstriction • positive regulation of NF-kappaB transcription factor activity • positive regulation of NAD(P)H oxidase activity • nitric oxide mediated signal transduction • G-protein coupled receptor signaling pathway coupled to cGMP nucleotide second messenger • positive regulation of epidermal growth factor receptor signaling pathway • regulation of blood volume by renin-angiotensin • regulation of cardiac conduction • regulation of blood vessel diameter by renin-angiotensin • regulation of renal sodium excretion • positive regulation of cytokine production • positive regulation of membrane hyperpolarization • negative regulation of sodium ion transmembrane transporter activity • renin-angiotensin regulation of aldosterone production • positive regulation of endothelial cell migration • low-density lipoprotein particle remodeling • regulation of cell proliferation • regulation of cell growth • positive regulation of gap junction assembly • positive regulation of phosphatidylinositol 3-kinase signaling • angiotensin-activated signaling pathway • negative regulation of gene expression • regulation of renal output by angiotensin • positive regulation of activation of Janus kinase activity • G-protein coupled receptor signaling pathway Sources:Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	183	11606
Ensembl	ENSG00000135744	ENSMUSG00000031980
UniProt	P01019	P11859 Q3UTR7
RefSeq (mRNA)	NM_000029 NM_001382817	NM_007428
RefSeq (protein)	NP_000020 NP_001369746	NP_031454
Location (UCSC)	Chr 1: 230.7 – 230.71 Mb	Chr 8: 124.56 – 124.57 Mb
PubMed search	[3]	[4]
Wikidata
View/Edit Human View/Edit Mouse

An oligopeptide, angiotensin is a hormone and a dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. Angiotensin was isolated in the late 1930s (first named 'angiotonin' or 'hypertensin') and subsequently characterized and synthesized by groups at the Cleveland Clinic and Ciba laboratories.[5]

Precursor and types

Angiotensinogen

Angiotensinogen is an α-2-globulin synthesized in the liver[6] and is a precursor for angiotensin, but has also been indicated as having many other roles not related to angiotensin peptides.[7] It is a member of the serpin family of proteins, leading to another name: Serpin A8,[8] although it is not known to inhibit other enzymes like most serpins. In addition, a generalized crystal structure can be estimated by examining other proteins of the serpin family, but angiotensinogen has an elongated N-terminus compared to other serpin family proteins.[9]

Angiotensinogen is also known as renin substrate. It is cleaved at the N-terminus by renin to result in angiotensin I, which will later be modified to become angiotensin II.[7][9] This peptide is 485 amino acids long, and 10 N-terminus amino acids are cleaved when renin acts on it.[7] The first 12 amino acids are the most important for activity.

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-...

Plasma angiotensinogen levels are increased by plasma corticosteroid, estrogen, thyroid hormone, and angiotensin II levels.

Angiotensin I

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu | Val-Ile-...

Renin–angiotensin–aldosterone system

Angiotensin I (CAS# 11128-99-7), officially called proangiotensin, is formed by the action of renin on angiotensinogen. Renin cleaves the peptide bond between the leucine (Leu) and valine (Val) residues on angiotensinogen, creating the decapeptide (ten amino acid) (des-Asp) angiotensin I. Renin is produced in the kidneys in response to renal sympathetic activity, decreased intrarenal blood pressure (<90mmHg systolic blood pressure[10] ) at the juxtaglomerular cells, or decreased delivery of Na+ and Cl- to the macula densa.[11] If a reduced NaCl concentration[12] in the distal tubule is sensed by the macula densa, renin release by juxtaglomerular cells is increased. This sensing mechanism for macula densa-mediated renin secretion appears to have a specific dependency on chloride ions rather than sodium ions. Studies using isolated preparations of thick ascending limb with glomerulus attached in low NaCl perfusate were unable to inhibit renin secretion when various sodium salts were added but could inhibit renin secretion with the addition of chloride salts.[13] This, and similar findings obtained in vivo,[14] has led some to believe that perhaps "the initiating signal for MD control of renin secretion is a change in the rate of NaCl uptake predominantly via a luminal Na,K,2Cl co-transporter whose physiological activity is determined by a change in luminal Cl concentration."[15]

Angiotensin I appears to have no direct biological activity and exists solely as a precursor to angiotensin II.

Angiotensin II

See also: Angiotensin II (medication)

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

Angiotensin I is converted to angiotensin II (AII) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung (but also present in endothelial cells, kidney epithelial cells, and the brain). Angiotensin II acts on the CNS to increase vasopressin production, and also acts on venous and arterial smooth muscle to cause vasoconstriction. Angiotensin II also increases aldosterone secretion; it therefore acts as an endocrine, autocrine/paracrine, and intracrine hormone.

ACE is a target of ACE inhibitor drugs, which decrease the rate of angiotensin II production. Angiotensin II increases blood pressure by stimulating the Gq protein in vascular smooth muscle cells (which in turn activates an IP3-dependent mechanism leading to a rise in intracellular calcium levels and ultimately causing contraction). In addition, angiotensin II acts at the Na⁺/H⁺ exchanger in the proximal tubules of the kidney to stimulate Na reabsorption and H⁺ excretion which is coupled to bicarbonate reabsorption. This ultimately results in an increase in blood volume, pressure, and pH.[16] Hence, ACE inhibitors are major anti-hypertensive drugs.

Other cleavage products of ACE, seven or nine amino acids long, are also known; they have differential affinity for angiotensin receptors, although their exact role is still unclear. The action of AII itself is targeted by angiotensin II receptor antagonists, which directly block angiotensin II AT₁ receptors.

Angiotensin II is degraded to angiotensin III by angiotensinases located in red blood cells and the vascular beds of most tissues. It has a half-life in circulation of around 30 seconds, whereas, in tissue, it may be as long as 15–30 minutes.

Angiotensin II results in increased inotropy, chronotropy, catecholamine (norepinephrine) release, catecholamine sensitivity, aldosterone levels, vasopressin levels, and cardiac remodeling and vasoconstriction through AT1 receptors on peripheral vessels (conversely, AT2 receptors impair cardiac remodeling). This is why ACE inhibitors and ARBs help to prevent remodeling that occurs secondary to angiotensin II and are beneficial in CHF.[15]

Angiotensin III

Asp | Arg-Val-Tyr-Ile-His-Pro-Phe

Angiotensin III has 40% of the pressor activity of angiotensin II, but 100% of the aldosterone-producing activity. Increases mean arterial pressure. It is a peptide that is formed by removing an amino acid from angiotensin II by aminopeptidase A [17]

Angiotensin IV

Arg | Val-Tyr-Ile-His-Pro-Phe

Angiotensin IV is a hexapeptide that, like angiotensin III, has some lesser activity. Angiotensin IV has a wide range of activities in the central nervous system.[18][19]

The exact identity of AT4 receptors has not been established. There is evidence that the AT4 receptor is insulin-regulated aminopeptidase (IRAP).[20] There is also evidence that angiotensin IV interacts with the HGF system through the c-Met receptor.[21][22]

Synthetic small molecule analogues of angiotensin IV with the ability to penetrate through blood brain barrier have been developed.[22]

The AT4 site may be involved in memory acquisition and recall, as well as blood flow regulation.[23]

Effects

See also Renin–angiotensin system#Effects

Angiotensins II, III and IV have a number of effects throughout the body:

Adipic

Angiotensins "modulate fat mass expansion through upregulation of adipose tissue lipogenesis ... and downregulation of lipolysis."[24]

Cardiovascular

They are potent direct vasoconstrictors, constricting arteries and veins and increasing blood pressure. This effect is achieved through activation of the GPCR AT1, which signals through a Gq protein to activate Phospholipase C, and subsequently increase intracellular calcium.[25]

Angiotensin II has prothrombotic potential through adhesion and aggregation of platelets and stimulation of PAI-1 and PAI-2.[26][27]

When cardiac cell growth is stimulated, a local (autocrine-paracrine) renin–angiotensin system is activated in the cardiac myocyte, which stimulates cardiac cell growth through protein kinase C. The same system can be activated in smooth muscle cells in conditions of hypertension, atherosclerosis, or endothelial damage. Angiotensin II is the most important Gq stimulator of the heart during hypertrophy, compared to endothelin-1 and α1 adrenoreceptors.

Neural

Angiotensin II increases thirst sensation (dipsogen) through the area postrema and subfornical organ of the brain,[28][29][30] decreases the response of the baroreceptor reflex, increases the desire for salt, increases secretion of ADH from the posterior pituitary, and increases secretion of ACTH from the anterior pituitary.[28] It also potentiates the release of norepinephrine by direct action on postganglionic sympathetic fibers.

Adrenal

Angiotensin II acts on the adrenal cortex, causing it to release aldosterone, a hormone that causes the kidneys to retain sodium and lose potassium. Elevated plasma angiotensin II levels are responsible for the elevated aldosterone levels present during the luteal phase of the menstrual cycle.

Renal

Angiotensin II has a direct effect on the proximal tubules to increase Na⁺ reabsorption. It has a complex and variable effect on glomerular filtration and renal blood flow depending on the setting. Increases in systemic blood pressure will maintain renal perfusion pressure; however, constriction of the afferent and efferent glomerular arterioles will tend to restrict renal blood flow. The effect on the efferent arteriolar resistance is, however, markedly greater, in part due to its smaller basal diameter; this tends to increase glomerular capillary hydrostatic pressure and maintain glomerular filtration rate. A number of other mechanisms can affect renal blood flow and GFR. High concentrations of Angiotensin II can constrict the glomerular mesangium, reducing the area for glomerular filtration. Angiotensin II is a sensitizer to tubuloglomerular feedback, preventing an excessive rise in GFR. Angiotensin II causes the local release of prostaglandins, which, in turn, antagonize renal vasoconstriction. The net effect of these competing mechanisms on glomerular filtration will vary with the physiological and pharmacological environment.

Direct Renal effects of angiotensin II (not including aldosterone release)

Target	Action	Mechanism[31]
renal artery & afferent arterioles	vasoconstriction (weaker)	VDCCs → Ca^2+ influx
efferent arteriole	vasoconstriction (stronger)	(probably) activate Angiotensin receptor 1 → Activation of Gq → ↑PLC activity → ↑IP3 and DAG → activation of IP3 receptor in SR → ↑intracellular Ca^2+
mesangial cells	contraction → ↓filtration area	activation of Gq → ↑PLC activity → ↑IP3 and DAG → activation of IP3 receptor in SR → ↑intracellular Ca^2+ VDCCs → Ca^2+ influx
proximal tubule	increased Na^+ reabsorption	adjustment of Starling forces in peritubular capillaries to favour increased reabsorption efferent and afferent arteriole contraction → decreased hydrostatic pressure in peritubular capillaries efferent arteriole contraction → increased filtration fraction → increased colloid osmotic pressure in peritubular capillaries increased sodium–hydrogen antiporter activity
tubuloglomerular feedback	increased sensitivity	increase in afferent arteriole responsiveness to signals from macula densa
medullary blood flow	reduction

See also

• ACE inhibitor
• Angiotensin receptor
• Angiotensin II receptor antagonist
• Captopril
• Perindopril
• Renin inhibitor

References

1. GRCh38: Ensembl release 89: ENSG00000135744 - Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000031980 - Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Basso N, Terragno NA (December 2001). "History about the discovery of the renin-angiotensin system". Hypertension. 38 (6): 1246–9. doi:10.1161/hy1201.101214. PMID 11751697.
6. "Angiotensin | Hormone Health Network". www.hormone.org. Retrieved 2019-12-02.
7. Lu, Hong; Cassis, Lisa A.; Kooi, Craig W. Vander; Daugherty, Alan (July 2016). "Structure and functions of angiotensinogen". Hypertension Research. 39 (7): 492–500. doi:10.1038/hr.2016.17. ISSN 1348-4214. PMC 4935807. PMID 26888118.
8. "AGT - Angiotensinogen precursor - Homo sapiens (Human) - AGT gene & protein". www.uniprot.org. Retrieved 2019-12-02.
9. Streatfeild-James, Rosa M. A.; Williamson, David; Pike, Robert N.; Tewksbury, Duane; Carrell, Robin W.; Coughlin, Paul B. (1998). "Angiotensinogen cleavage by renin: importance of a structurally constrained N-terminus". FEBS Letters. 436 (2): 267–270. doi:10.1016/S0014-5793(98)01145-4. ISSN 1873-3468. PMID 9781693.
10. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ (October 1998). "Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents". JAMA. 280 (13): 1168–72. doi:10.1001/jama.280.13.1168. PMID 9777817.
11. Williams GH, Dluhy RG (2008). "Chapter 336: Disorders of the Adrenal Cortex". In Loscalzo J, Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL (eds.). Harrison's principles of internal medicine. McGraw-Hill Medical. ISBN 978-0-07-146633-2.
12. Skott O, Briggs JP (1987). "Direct demonstration of macula densa-mediated renin secretion". Science. 237 (4822): 1618–1620. Bibcode:1987Sci...237.1618S. doi:10.1126/science.3306925. PMID 3306925.
13. Kirchner KA, Kotchen TA, Galla JH, Luke RG (November 1978). "Importance of chloride for acute inhibition of renin by sodium chloride". The American Journal of Physiology. 235 (5): F444–50. doi:10.1152/ajprenal.1978.235.5.F444. PMID 31796.
14. Kim SM, Mizel D, Huang YG, Briggs JP, Schnermann J (May 2006). "Adenosine as a mediator of macula densa-dependent inhibition of renin secretion". American Journal of Physiology. Renal Physiology. 290 (5): F1016–23. doi:10.1152/ajprenal.00367.2005. PMID 16303857.
15. Schnermann JB, Castrop H (2013). "Chapter 23: Function of the juxtaglomerular apparatus: control of glomerular hemodynamics and renin secretion.". In Alpern RJ, Moe OW, Caplan M (eds.). Seldin and Giebisch's The Kidney (Fifth ed.). Academic Press. pp. 757–801. doi:10.1016/B978-0-12-381462-3.00023-9. ISBN 978-0-12-381462-3.
16. Le T (2012). First Aid for the Basic Sciences. Organ Systems. McGraw-Hill. p. 625.
17. "Angiotensin III". PubChem. NIH. Retrieved 9 May 2019.
18. Chai SY, Fernando R, Peck G, Ye SY, Mendelsohn FA, Jenkins TA, Albiston AL (November 2004). "The angiotensin IV/AT4 receptor". Cellular and Molecular Life Sciences. 61 (21): 2728–37. doi:10.1007/s00018-004-4246-1. PMID 15549174.
19. Gard PR (December 2008). "Cognitive-enhancing effects of angiotensin IV". BMC Neuroscience. 9 Suppl 2: S15. doi:10.1186/1471-2202-9-S2-S15. PMC 2604899. PMID 19090988.
20. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY (December 2001). "Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase". The Journal of Biological Chemistry. 276 (52): 48623–6. doi:10.1074/jbc.C100512200. PMID 11707427.
21. Wright JW, Harding JW (2015-01-01). "The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease". Journal of Alzheimer's Disease. 45 (4): 985–1000. doi:10.3233/JAD-142814. PMID 25649658.
22. Wright JW, Kawas LH, Harding JW (February 2015). "The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases". Progress in Neurobiology. 125: 26–46. doi:10.1016/j.pneurobio.2014.11.004. PMID 25455861.
23. Wright JW, Krebs LT, Stobb JW, Harding JW (January 1995). "The angiotensin IV system: functional implications". Frontiers in Neuroendocrinology. 16 (1): 23–52. doi:10.1006/frne.1995.1002. PMID 7768321.
24. Yvan-Charvet L, Quignard-Boulangé A (January 2011). "Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity". Kidney International. 79 (2): 162–8. doi:10.1038/ki.2010.391. PMID 20944545.
25. Kanaide H, Ichiki T, Nishimura J, Hirano K (November 2003). "Cellular mechanism of vasoconstriction induced by angiotensin II: it remains to be determined". Circulation Research. 93 (11): 1015–7. doi:10.1161/01.RES.0000105920.33926.60. PMID 14645130.
26. Skurk T, Lee YM, Hauner H (May 2001). "Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture". Hypertension. 37 (5): 1336–40. doi:10.1161/01.HYP.37.5.1336. PMID 11358950. Archived from the original on 2013-01-12.
27. Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, Schena FP, Ursi M, Cerullo G (August 1999). "Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells". Kidney International. 56 (2): 461–70. doi:10.1046/j.1523-1755.1999.00578.x. PMID 10432384.
28. Johnson AK, Gross PM (May 1993). "Sensory circumventricular organs and brain homeostatic pathways". FASEB Journal. 7 (8): 678–86. doi:10.1096/fasebj.7.8.8500693. PMID 8500693.
29. Shaver SW, Kadekaro M, Gross PM (December 1989). "High metabolic activity in the dorsal vagal complex of Brattleboro rats". Brain Research. 505 (2): 316–20. doi:10.1016/0006-8993(89)91459-5. PMID 2598049.
30. Gross PM, Wainman DS, Shaver SW, Wall KM, Ferguson AV (March 1990). "Metabolic activation of efferent pathways from the rat area postrema". The American Journal of Physiology. 258 (3 Pt 2): R788-97. doi:10.1152/ajpregu.1990.258.3.R788. PMID 2316724.
31. Boulpaep EL, Boron WF (2005). Medical Physiology: a Cellular and Molecular Approach. St. Louis, Mo: Elsevier Saunders. p. 771. ISBN 978-1-4160-2328-9.

Further reading

• de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (September 2000). "International union of pharmacology. XXIII. The angiotensin II receptors". Pharmacological Reviews. 52 (3): 415–72. PMID 10977869.
• Brenner & Rector's The Kidney, 7th ed., Saunders, 2004.
• Mosby's Medical Dictionary, 3rd Ed., CV Mosby Company, 1990.
• Review of Medical Physiology, 20th Ed., William F. Ganong, McGraw-Hill, 2001.
• Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed., Burton David Rose & Theodore W. Post McGraw-Hill, 2001
• Lees KR, MacFadyen RJ, Doig JK, Reid JL (August 1993). "Role of angiotensin in the extravascular system". Journal of Human Hypertension. 7 Suppl 2: S7-12. PMID 8230088.
• Weir MR, Dzau VJ (December 1999). "The renin-angiotensin-aldosterone system: a specific target for hypertension management". American Journal of Hypertension. 12 (12 Pt 3): 205S–213S. doi:10.1016/S0895-7061(99)00103-X. PMID 10619573.
• Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG (December 2001). "Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide". American Journal of Physiology. Heart and Circulatory Physiology. 281 (6): H2337-65. doi:10.1152/ajpheart.2001.281.6.H2337. PMID 11709400.
• Sernia C (January 2001). "A critical appraisal of the intrinsic pancreatic angiotensin-generating system". Journal of the Pancreas. 2 (1): 50–5. PMID 11862023.
• Varagic J, Frohlich ED (November 2002). "Local cardiac renin-angiotensin system: hypertension and cardiac failure". Journal of Molecular and Cellular Cardiology. 34 (11): 1435–42. doi:10.1006/jmcc.2002.2075. PMID 12431442.
• Wolf G (2006). "Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis". Antioxidants & Redox Signaling. 7 (9–10): 1337–45. doi:10.1089/ars.2005.7.1337. PMID 16115039.
• Cazaubon S, Deshayes F, Couraud PO, Nahmias C (April 2006). "[Endothelin-1, angiotensin II and cancer]". Médecine/Sciences. 22 (4): 416–22. doi:10.1051/medsci/2006224416. PMID 16597412.
• Ariza AC, Bobadilla NA, Halhali A (2007). "[Endothelin 1 and angiotensin II in preeeclampsia]". Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion. 59 (1): 48–56. PMID 17569300.

External links

• The MEROPS online database for peptidases and their inhibitors: I04.953
• Angiotensins at the US National Library of Medicine Medical Subject Headings (MeSH)
• Human AGT genome location and AGT gene details page in the UCSC Genome Browser.
• Overview of all the structural information available in the PDB for UniProt: P01019 (Angiotensin) at the PDBe-KB.